Feature|Articles|December 29, 2023

The Top 5 Q&As of 2023

Author(s)Mike Hollan

Pharm Exec spent the year speaking with some of the most interesting professionals from the life sciences industry.

Q&A: How Does a ‘Never Enough’ Achievement Culture Impact Your Workforce’s Morale? Planning for 2024 With Journalist and Author Jennifer Breheny Wallace

Jennifer Breheny Wallace, award-winning journalist and author, notes that C-Suite leaders should understand the financial risks of not taking action to address workplace burnout in 2024.

Reacting to Trends: Q&A With Leslie Orne, CEO of Trinity Life Sciences

Orne discusses the forces impacting the life sciences market and how companies are reacting.

Q&A With Kevin O'Neill, president and CEO of GE HealthCare, Pharmaceutical Diagnostics

O'Neill discusses the company's place in the global market and recent advancements to improve the patient experience.

The Changing Prescriber Communications Dynamic: Q&A with Caleb Costa, Chief Customer Officer at InCrowd

Explore the changing dynamics of healthcare professionals' communication preferences in a post-pandemic world, as Pharm Exec's Fran Pollaro has a no frills discussion about InCrowd's latest insights with chief customer officer Caleb Costa.

Threads, the Twitter Competitor's Impact on Pharma Marketing: Q&A with Justin Chase

An insightful discussion about how Meta's newest social media platform, Threads, is quickly adding another facet to the digital landscape for pharma marketers.

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.